tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

COGT Stock Latest News

Cogent Biosciences price target raised to $35 from $34 at Baird
The FlyCogent Biosciences price target raised to $35 from $34 at Baird
1d ago
COGT
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
PremiumRatings
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
2d ago
COGT
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
PremiumThe Fly
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
2d ago
COGT
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
PremiumCompany Announcements
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
2d ago
COGT
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
PremiumThe Fly
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
3d ago
COGT
Cogent Biosciences sees cash runway into 2028
PremiumThe FlyCogent Biosciences sees cash runway into 2028
3d ago
COGT
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
Premium
Ratings
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
25d ago
COGT
Cogent Biosciences announcse U.S. BTD for bezuclastinib
Premium
The Fly
Cogent Biosciences announcse U.S. BTD for bezuclastinib
25d ago
COGT
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
PremiumCompany Announcements
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
28d ago
COGT
Cogent to initiate New Drug Application submission for bezuclastinib
PremiumThe Fly
Cogent to initiate New Drug Application submission for bezuclastinib
1M ago
COGT
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
PremiumRatings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
1M ago
COGT
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
PremiumThe Fly
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
1M ago
COGT
Aligos Therapeutics initiated with a Buy at UBS
PremiumThe FlyAligos Therapeutics initiated with a Buy at UBS
1M ago
IVA
KOD
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
2M ago
COGT
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
Premium
The Fly
Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright
2M ago
COGT
Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM
PremiumThe Fly
Cogent Biosciences submits NDA for bezuclastinib in NonAdvSM
2M ago
COGT
Cogent Biosciences price target raised to $67 from $65 at JPMorgan
PremiumThe Fly
Cogent Biosciences price target raised to $67 from $65 at JPMorgan
2M ago
COGT
Cogent Biosciences Reports Positive Clinical Trial Results
PremiumCompany Announcements
Cogent Biosciences Reports Positive Clinical Trial Results
2M ago
8K
COGT
Cogent Biosciences price target raised to $48 from $45 at Jefferies
PremiumThe Fly
Cogent Biosciences price target raised to $48 from $45 at Jefferies
2M ago
COGT
Cogent Biosciences announces results of APEX trial of bezuclastinib
PremiumThe FlyCogent Biosciences announces results of APEX trial of bezuclastinib
2M ago
COGT
Cogent Biosciences presents full SUMMIT results of bezuclastinib
Premium
The Fly
Cogent Biosciences presents full SUMMIT results of bezuclastinib
2M ago
COGT
Cogent Biosciences Completes $230M Convertible Notes Offering
Premium
Company Announcements
Cogent Biosciences Completes $230M Convertible Notes Offering
3M ago
8K
COGT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >